Portland, OR -- (SBWIRE) -- 08/17/2017 -- Atrial Fibrillation refers to quivering or irregular heartbeat (also termed as arrhythmia) that can lead to blood clots, stroke, heart failure, and other heart-related complications. The symptoms of atrial fibrillation include confusion, dizziness, fatigue, and fainting.

Early buyers will receive 20% customization on this report.

Rise in prevalence of atrial fibrillation in geriatric population, technological advancements, and increase in preference of catheter ablation for cardiac arrhythmia treatment drive the market. However, unfavorable preference to pharmaceutical interventions (drugs) over atrial fibrillation treatment devices restrain this growth. The growth opportunities in emerging economies of Asia-Pacific and LAMEA are expected to provide numerous opportunities for market growth during the forecast period.

The report segments the market based on procedure and geography. Based on procedure, the market is divided into catheter ablation and surgical ablation. Geographically, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Request for Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/2127

The major companies profiled in the report include Biosense Webster, Inc., Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, AtriCure Inc., Biotronik SE & Co. KG, Cardiofocus, Inc., Ncontact, Inc., and Carima, Inc.